会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 24. 发明授权
    • Pharmaceutical compositions and methods for increasing zinc levels
    • 用于增加锌含量的药物组合物和方法
    • US4665064A
    • 1987-05-12
    • US666905
    • 1984-10-31
    • Robert C. HiderGeorge KontoghiorghesJack SilverMichael A. Stockham
    • Robert C. HiderGeorge KontoghiorghesJack SilverMichael A. Stockham
    • A23K1/175A61K31/44A61K31/4412A61K31/4418A61K31/4425A61K31/555A61P3/00C07D213/69C07D309/40
    • C07D213/69A23K20/30C07D309/40
    • Zinc(II) complexes in which at least one ligand is provided by a compound being:(1) 3-hydroxy-4-pyrone or a 3-hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms; or(2) a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionizable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group; are of value in medicine, particularly in the systemic treatment of zinc depletion. Mixtures of these zinc complexes with the metal-free compound(s) providing the ligands contained therein and with iron(III) complexes containing ligands of types (1) and (2) are also of value.
    • 锌(II)络合物,其中至少一种配体由以下化合物提供:(1)3-羟基-4-吡喃酮或其中一个或多个与环碳连接的氢原子的3-羟基-4-吡喃酮 原子被1至6个碳原子的脂族烃基取代; 或(2)通过1〜6个碳原子的脂族烃基,其中与氮原子连接的氢原子被脂肪族酰基取代的3-羟基吡啶-2-酮或3-羟基吡啶-4-酮, 或通过被一个取代的脂肪族烃基,或者除了可离子化基团以外的多个选自脂肪族酰基,烷氧基,脂肪族胺,脂肪族酰胺,羧基,脂肪族酯,卤素,羟基和磺基的取代基的脂肪族烃基, 其中一个或多个与环碳原子连接的氢原子被一个所述取代基取代,被1至6个碳原子的脂族烃基取代,或被被烷氧基,脂族酯,卤素取代的脂族烃基取代 或羟基; 在药物中具有价值,特别是在锌耗竭的全身治疗中。 这些锌配合物与提供其中所含配体的金属化合物和含有(1)和(2)类型配体的铁(III)配合物的混合物也是有价值的。